Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Alicia Smucler-Simonovich"'
Autor:
Erik de Cabo López, Ma. Jesús Vidal-Manceñido, Josefina Galende del Canto, Carmen Aguilera Sanz, Marta Megido Lahera, Alicia Smucler Simonovich, Sheila Bodelón Gago, Carlos A. Cuenca Aprell
Publikováno v:
Revista Sangre (ENG). 41
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f95905e96b17d0d2a91318311bf64939
https://doi.org/10.24875/sangree.22000003
https://doi.org/10.24875/sangree.22000003
Autor:
Erik de Cabo López, Ma. Jesús Vidal-Manceñido, Josefina Galende del Canto, Carmen Aguilera Sanz, Marta Megido Lahera, Alicia Smucler Simonovich, Sheila Bodelón Gago, Carlos A. Cuenca Aprell
Publikováno v:
Revista Sangre. 41
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b2c5fba5d4f5ac20fc170028e9bc659b
https://doi.org/10.24875/sangre.m22000005
https://doi.org/10.24875/sangre.m22000005
Autor:
Cristina Loriente, Inmaculada Pérez, Montserrat López Rubio, Ana Cristina Godoy, María del Carmen Losada Castillo, Carolina Cuellar-García, Eduardo Ríos, Lucrecia Yáñez, Maria Dolores Garcia Malo, Ana Lario, Pau Abrisqueta, Julio Delgado, Mª José Berruezo, Alicia Smucler Simonovich, Alicia Rodríguez, Rafael Ramos, Miguel Villanueva, José Mª Arguiñano Pérez, Daniel Acha, Margarita Fernández de la Mata, Isidro Jarque, Javier Loscertales, Jose Luis Bello, Santiago Osorio, Paloma Martin, Angel Ramirez Payer, Macarena Ortiz, Ernesto Pérez Persona, Rubén Fernández Álvarez, Aima Lancharro Anchel, Jose Angel Hernandez-Rivas, Miguel Fernández-Zarzoso, Ana Célia Carneiro Oliveira, Patricia Baltasar, Angeles Medina, Mª Jesús Vidal Manceñido, Alexia Suarez, Ricardo García Muñoz, María José Terol, Fernando De Marco
Publikováno v:
Clinical lymphoma, myeloma & leukemia
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
r-FISABIO. Repositorio Institucional de Producción Científica
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
Dipòsit Digital de la UB
Universidad de Barcelona
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
r-FISABIO. Repositorio Institucional de Producción Científica
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
Dipòsit Digital de la UB
Universidad de Barcelona
Ibrutinib demonstrated robust efficacy, regardless of high-risk features, in previously untreated or relapsed/refractory chronic lymphocytic leukemia (CLL). The IBRORS-CLL study supports the effectiveness and the manageable safety profile of single-a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46c4f2a1bd607572095c4a75307637b0
https://pubmed.ncbi.nlm.nih.gov/34511320
https://pubmed.ncbi.nlm.nih.gov/34511320
Autor:
Alicia Smucler Simonovich, Eduardo Ríos Herranz, José A. Márquez, Sandra Iraheta, Angel Ramirez Payer, Macarena Ortiz, Javier Loscertales, Ernesto Pérez Persona, Jose Manuel Puerta, María José Terol, Javier de la Serna, Patricia Baltasar, José A. García-Marco, Begoña Muiña, Tomas García, Rafael Andreu, Fatima De la Cruz, Ana Muntañola Prat, Gonzalo Caballero, Diana Moreno, Marcos González Díaz, Ruben Fernandez, Juan Marquet Palomanes, Laura Magnano, Carol Moreno, María Angeles Andreu, Jose M Arguiñano, Ana Ruiz-Zorrilla, Santiago Osorio, Lucrecia Yáñez, Christelle Ferra, Manuel Pérez-Encinas
Publikováno v:
Blood. 138:1561-1561
Introduction: The BCL-2 inhibitor venetoclax (Ven) has been approved on monotherapy or combined with rituximab in relapsed/refractory CLL patients (pts) and combined with obinutuzumab in previously untreated CLL pts. However, evidence from clinical t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::731ff73828e032141aa4a86575105c96
https://doi.org/10.1182/blood-2021-147685
https://doi.org/10.1182/blood-2021-147685
Autor:
Jose M Arguiñano, Angeles Medina, Ana Lario, Santiago Osorio-Prendes, Javier Loscertales, Lucrecia Yáñez, Patricia Baltasar, Fernando De Marco, Julio Delgado, Margarita Fernández de la Mata, Macarena Ortiz Pareja, Miguel Ganuza Fernandez, Inmaculada Pérez, Alicia Rodríguez, Rafael Ramos, Ana Cristina Godoy, Ruben Fernandez, Alexia Suárez Cabrera, Jose Luis Bello, Jose Angel Hernandez-Rivas, Carmen Losada, Montserrat López Rubio, Aima Lancharro Anchel, María-Jesús Vidal, Eduardo Rios Herranz, Angel Ramirez Payer, Isidro Jarque, Ana Célia Carneiro Oliveira, Maria José Berruezo, Pau Abrisqueta Costa, Carolina Cuellar, Paloma Martin, María-Dolores García-Malo, Ernesto Pérez Persona, María José Terol, Cristina Loriente, Alicia Smucler Simonovich, Ricardo Francisco Garcia, Miguel Villanueva
Publikováno v:
Blood. 136:32-33
Introduction. Ibrutinib is a first-in-class, oral, once-a-day Bruton's tyrosine kinase inhibitor that achieves high overall response rates and durable remissions in patients with chronic lymphocytic leukemia (CLL) including those with high-risk featu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d76bf26c288ba86c1684e5da66b1577d
https://doi.org/10.1182/blood-2020-136036
https://doi.org/10.1182/blood-2020-136036
Publikováno v:
The American Journal of Dermatopathology. 33:819-826
The differential diagnosis between primary cutaneous diffuse large B-cell lymphoma and cutaneous follicular lymphoma is one of the most difficult aspects of dermatopathology, even though morphological criteria are well established and a wide panel of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::590923669624aa7ed9264cf08b848410
https://doi.org/10.1097/dad.0b013e3181fe9746
https://doi.org/10.1097/dad.0b013e3181fe9746